Article info

Download PDFPDF

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Authors

  1. Correspondence to Dr Seza Ozen, Department of Pediatric Rheumatology, Hacettepe University, Ankara 06800, Turkey; sezaozen{at}gmail.com
View Full Text

Citation

Ozen S, Ben-Cherit E, Foeldvari I, et al
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Publication history

  • Received March 25, 2020
  • Revised May 28, 2020
  • Accepted May 29, 2020
  • First published June 22, 2020.
Online issue publication 
September 14, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.